MedPath

Clindamycin

Generic Name
Clindamycin
Brand Names
Acanya, Benzaclin, Biacna, Cabtreo, Cleocin, Cleocin-T, Clindacin, Clindagel, Clindesse, Clindoxyl, Dalacin, Dalacin C, Duac, Evoclin, Neuac, Onexton, Veltin, Xaciato, Ziana
Drug Type
Small Molecule
Chemical Formula
C18H33ClN2O5S
CAS Number
18323-44-9
Unique Ingredient Identifier
3U02EL437C
Background

Clindamycin is a semi-synthetic lincosamide antibiotic used in the treatment of a variety of serious infections due to susceptible microorganisms as well as topically for acne vulgaris. It has a relatively narrow spectrum of activity that includes anaerobic bacteria as well as gram-positive cocci and bacilli and gram-negative bacilli. Interestingly, clindamycin appears to carry some activity against protozoans, and has been used off-label in the treatment of toxoplasmosis, malaria, and babesiosis.

Clindamycin is derived from, and has largely replaced, lincomycin, a naturally occurring lincosamide and the eponymous member of this antibiotic class, due to its improved properties over the parent compound. The name lincomycin is derived from Lincoln, Nebraska, where it was first isolated from Streptomyces lincolnensis found in a soil sample.

Indication

In oral and parenteral formulations, clindamycin is indicated for the treatment of serious infections caused by susceptible anaerobic bacteria, as well as susceptible staphylococci, streptococci, and pneumococci. Used topically, it is indicated for the treatment of acne vulgaris and is available in combination with benzoyl peroxide or tretinoin for this purpose, or as a triple combination therapy with benzoyl peroxide and adapalene. Clindamycin is also indicated as a vaginal cream, suppository, or gel for the treatment of bacterial vaginosis in non-pregnant females.

Clindamycin is used for antimicrobial prophylaxis against Viridans group streptococcal infections in susceptible patients undergoing oral, dental, or upper respiratory surgery, and may be used for prophylaxis against bacterial endocarditis in penicillin-allergic patients at high risk of these infections.

Associated Conditions
Abscess, Intra-Abdominal caused by Anaerobic Bacterial Infection, Acne Vulgaris, Babesiosis, Bacterial Endocarditis, Bacterial Vaginosis (BV), Bloodstream Infections caused by Anaerobic Bacterial Infection, Bone and Joint Infections caused by susceptible Staphylococcus, Empyema caused by Anaerobic Bacterial Infection, Endometritis caused by Anaerobic Bacterial Infection, Lung Abscess caused by Anaerobic Bacterial Infection, Malaria caused by Plasmodium falciparum, Mixed Vaginal Infections, Pelvic cellulitis caused by Anaerobic Bacterial Infection, Peritonitis caused by Anaerobic Bacterial Infection, Pneumocystis Jirovecii Pneumonia, Pneumonitis caused by Anaerobic Bacterial Infection, Respiratory Tract Infections (RTI) caused by susceptible Staphylococcus, Respiratory Tract Infections (RTI) caused by susceptible pneumococci, Respiratory Tract Infections (RTI) caused by susceptible streptococci, Septicemia caused by susceptible Staphylococcus, Septicemia caused by susceptible streptococci, Skin Structures and Soft Tissue Infections caused by Anaerobic Bacterial Infection, Skin Structures and Soft Tissue Infections caused by susceptible Staphylococcus, Skin Structures and Soft Tissue Infections caused by susceptible streptococci, Toxoplasmosis, Tubo-ovarian abscess caused by Anaerobic Bacterial Infection, Vaginal Candidiasis, Vaginal Mycosis, Chronic Bone and Joint Infections caused by Susceptible infections, Moderate Acne vulgaris, Post-surgical vaginal cuff infection caused by Anaerobic Bacterial Infection, Viridans group streptococci
Clinical Trials
Related News

Daré Bioscience Fast-Tracks Sildenafil Cream Launch with Dual-Market Strategy for Women's Health

• Daré Bioscience has unveiled a dual-path approach to make its proprietary Sildenafil Cream formulation available via prescription by Q4 2025, responding to healthcare community urging and women's demand. • The company is exploring a 503B compounding pathway to accelerate market access for its female sexual arousal disorder (FSAD) treatment, potentially creating the first FDA-approved therapy for this condition. • CEO Sabrina Martucci Johnson will present the expanded business strategy at the Jones Healthcare and Technology Innovation Conference, with plans to evaluate similar approaches for other proprietary formulations in their portfolio.

XOMA Royalty Expands Portfolio to Over 120 Assets, Reports Financial Results for 2024

• XOMA Royalty doubled its portfolio to over 120 royalty assets through five strategic transactions in 2024, strengthening its position as a biotech royalty aggregator. • The company completed two whole company acquisitions and celebrated FDA approvals for Day One's OJEMDA™ (tovorafenib) and Zevra's MIPLYFFA™ (arimoclomol), generating significant milestone payments. • Despite reporting a net loss of $13.8 million for 2024, XOMA Royalty received $46.3 million in cash receipts and maintains over $100 million in cash, positioning it for sustainable cashflow from royalties.

Partner Treatment Halves Bacterial Vaginosis Recurrence Rate in Landmark Trial

• A groundbreaking randomized controlled trial demonstrates that treating both women and their male partners for bacterial vaginosis reduces recurrence rates by nearly 50% compared to treating women alone. • The study, conducted at Monash University, provides substantial evidence that bacterial vaginosis is sexually transmitted, challenging current treatment approaches for this condition affecting 21 million U.S. women. • Male partners treated with oral metronidazole and topical clindamycin resulted in a significant reduction in BV recurrence rate from 4.2 to 1.6 per person-year in female partners.

Daré Bioscience Advances Women's Health Portfolio with Funding and Clinical Progress

• Daré Bioscience is progressing its hormone-free contraceptive, Ovaprene, in a Phase 3 efficacy study, boosted by a foundation grant to expand clinical sites. • Sildenafil Cream 3.6% for female sexual arousal disorder is advancing towards Phase 3 after constructive FDA discussions on trial design and endpoints. • DARE-HPV, a novel treatment for HPV-related cervical diseases, is set for a Phase 2 trial, supported by a $10 million ARPA-H award. • Activities are underway for Phase 2 and Phase 1 studies of DARE-VVA1 and DARE-PTB1, respectively, targeting dyspareunia and preterm birth prevention.
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy